318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

M Gogishvili,T Melkadze,T Makharadze,D Giorgadze,M Dvorkin,K.D Penkov,K Laktionov,G Nemsadze,M Nechaeva,I Rozhkova,E Kalinka,C Gessner,B Moreno Jaime,R Passalacqua,S Li,K Mcguire,R.G Quek,G Gullo,P Rietschel

doi:10.1016/j.annonc.2022.10.361

318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

M Gogishvili, T Melkadze + Show 17 more

https://doi.org/10.1016/j.annonc.2022.10.361

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Nov 1, 2022

Affiliation: Med Center, David Tvildiani Medical University

#Non-small Cell Lung Cancer #Platinum-based Chemo + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

EMPOWER-Lung 3 is a randomised, 2-part, Phase 3 study of 1L treatment of patients (pts) with advanced (Stage III/IV) squamous (SQ) or non-squamous (NSQ) NSCLC without actionable mutations (NCT03409614). The double-blind Part 2 of the study enrolled pts irrespective of PD-L1 levels and compared clinical activity and safety of cemiplimab, an anti-PD-1, plus (+) platinum-based chemo, versus (vs) placebo (PBO)+chemo.

Full Text